INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 444m ago
HOUSE PTR44m ago
SEC 13F44m ago
ROBINHOOD CHAIN44m ago
PV
Corporate insider

Poulton Jeffrey V.

EVP, Chief Financial OfficerCIK 0001782962

EDGAR filingsOpen in network
Disclosed transactions22
Buys / sells0 / 21
Max Insider Score39
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
19
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Grant or award
A—
6,193 sh
Jan 11, 2026Jan 14, 2026
traded Jan 11, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    ALNYLAM PHARMACEUTICALS, INC.EVP, Chief Financial Officer · Jan 14, 2026
36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL
$25K
72 sh
Jan 12, 2026
Jan 14, 2026
traded Jan 12, 2026
+2d
SEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$28K
78 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$27K
76 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$63K
176 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$81K
226 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$56K
156 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$102K
284 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$65K
181 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$49K
135 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$32K
87 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$28K
76 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$63K
170 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$27K
73 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$13K
36 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$9,361
25 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$13K
34 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$10K
27 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$148K
405 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$133K
365 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$2,235
6 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence